胡 名宏

Medicine & Life Sciences

1. Triple Negative Breast Neoplasms 100%
2. Hematopoietic Stem Cell Transplantation 88%
3. Lapatinib 78%
4. Cholangiocarcinoma 63%
5. Apoptosis 49%
6. protein phosphatase 5 49%
7. eribulin 45%
8. Breakthrough Pain 41%
9. Protein Phosphatase 2 35%
10. Invasive Fungal Infections 35%
11. Erlotinib Hydrochloride 35%
12. Gefitinib 34%
13. Fish Oils 34%
14. src Homology Domains 33%
15. Cancer Pain 32%
16. Idiopathic Thrombocytopenic Purpura 32%
17. Pericardial Effusion 32%
18. Graft vs Host Disease 32%
19. Lymphoma, Large B-Cell, Diffuse 31%
20. Threonine 30%
21. Endoplasmic Reticulum Stress 30%
22. Selenium 30%
23. Omega-3 Fatty Acids 30%
24. Lymphocyte Count 30%
25. Rituximab 29%
26. Response Elements 29%
27. Adenocarcinoma of Lung 29%
28. Phosphoric Monoester Hydrolases 28%
29. Pain Management 27%
30. Taiwan 27%
31. Serine 26%
32. Survival 25%
33. Opioid Analgesics 24%
34. Multicenter Studies 24%
35. Neoplasms 22%
36. Diabetes Mellitus 21%
37. Observational Studies 21%
38. Thrombosis 21%
39. Therapeutics 21%
40. Fentanyl 19%
41. Anticoagulants 19%
42. Stroke 18%
43. Drug Therapy 18%
44. Retrospective Studies 18%
45. Recurrence 18%
46. Dabigatran 18%
47. Breast Neoplasms 17%
48. AMP-Activated Protein Kinases 16%
49. Incidence 16%
50. Non-Small Cell Lung Carcinoma 14%